Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Portfolio Building Block World Pharma and Biotech Index ETF(PBPH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PBPH
11/06/2026: PBPH (2-star) has a low Upturn Star Rating. Not recommended to BUY.
PBPH is a cost-effective, thematic ETF that tracks a global index of pure-play pharmaceutical and biotechnology companies. By focusing on firms that derive the majority of their revenue from therapeutics, it offers concentrated exposure to healthcare innovation. Its key strengths include a low expense ratio and a rules-based index approach. The primary risks involve the inherent volatility of drug development and potential regulatory impacts on pricing. It is best suited for growth-oriented investors looking to complement a core portfolio with specialized sector exposure, while monitoring clinical and legislative developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The focus on innovation-driven biotech provides significant growth potential for aggressive portfolios. |
| Momentum investor | Strong fit while signal remains positive | The sector's tendency for rapid price appreciation during drug development cycles makes it suitable for momentum strategies. |
| Value investor | Mixed fit | While large-cap pharma holdings may offer value, the biotech component often trades at higher growth-oriented valuations. |
| Dividend/Income investor | Weak fit | The fund is primarily focused on capital appreciation rather than high-yield income generation. |
| Low-risk investor | Weak fit | Biotechnology volatility can be substantial, making it unsuitable for capital preservation-focused investors. |
Investor Profile
Ideal Investor Profile
Investors seeking targeted, cost-effective global exposure to pharmaceutical and biotechnology innovation.
Suitability
Best for long-term investors looking to overweight the healthcare sector's growth potential within a diversified portfolio.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | Medium / high | Biotech stocks are prone to significant price swings based on clinical results and regulatory news. |
| Market risk | Medium | Equity market downturns typically impact healthcare stocks, though they are often seen as defensive. |
| Concentration | Medium / high | Focusing solely on pharma and biotech limits diversification across other sectors of the economy. |
| Tracking/expense | Low | The low expense ratio and physical replication minimize significant tracking error relative to the index. |
| Liquidity | Medium | Smaller or niche holdings within the biotech sector may experience lower liquidity during market stress. |
| Business/sector quality | Medium | Success is highly dependent on the R&D pipeline and regulatory approval processes of the underlying companies. |
Risk Analysis
Volatility
PBPH exhibits volatility characteristic of the healthcare and biotech sectors, which often outperform or underperform the broader market depending on innovation cycles.
Market Risk
The fund is subject to specific risks including clinical trial outcomes, FDA regulatory decisions, patent cliffs, and legislative pricing pressures.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Sector | Pharmaceuticals & Biotechnology (Global) | 98 | The fund provides concentrated exposure to the discovery, development, and commercialization of human therapeutics. |
| Cash/collateral | Cash and Cash Equivalents | 2 | Small allocation maintained for liquidity and operational management. |
Analysis of Past Performance
Type ETF | Historic Profit 20.01% | Avg. Invested days 67 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | ETF Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.